key: cord-0763071-7bk9ut9m
authors: Park, Sang Hyuk; Kim, Hyun-Ki; Kang, Hang; Kim, Jung Heon; Lee, Jaeseung; Lim, Ji-Hun; Lee, Seon-Ho; Jeong, Joseph
title: Incidence Evaluation of SARS-CoV-2 Variants in the Ulsan Area, Korea, Using PowerChek SARS-CoV-2 S-gene Mutation Detection Kit: A Pilot Study
date: 2022-05-01
journal: Ann Lab Med
DOI: 10.3343/alm.2022.42.3.363
sha: 6b0617c77debdc22b0a88e5d4b11bc0cf93903af
doc_id: 763071
cord_uid: 7bk9ut9m

nan

Dear Editor, In Korea, more than 130,000 cases of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), were recorded from January 1, 2020 to May 14, 2021, with approximately 600 cases diagnosed per day following published guidelines for the laboratory diagnosis of COVID-19 in Korea [1] . The number of SARS-CoV-2 variants has been increasing, posing a significant threat in terms of increased infectivity and clinical severity accompanied by reduced immunity upon vaccination [2] [3] [4] .

Most SARS-CoV-2 variants arise due to changes in the N-terminal domain (NTD) and receptor-binding domain (RBD) [4, 5] . Among NTD variants, the spike deletion H69/V70 (del69-70), which exerts a marginal effect on 50% neutralization values in plaque reduction neutralization tests of post-vaccination serum samples, is present in the B.1.1.7 variant that was initially dominant in the United Kingdom (UK) before spreading worldwide [6] . N501Y is the most prominent RBD variant, which improves SARS-CoV-2 binding affinity, and is present in the UK (B.1.1.7), the Republic of South Africa (RSA) (B.1.351), and Brazil/Japan (P.1.) variants [4, 6] . In addition, K417N, which can improve the receptor binding of SARS-CoV-2, is present in the RSA variant B.1.351, and E484K, associated with immune escape from monoclonal antibodies, has been detected in both the RSA and Brazilian variants [4, 7, 8] .

PowerChek Table 1 .

Using rRT-PCR, N501Y, E484K, and K417N were detected in 34 (94.4%), 1 (2.8%), and 0 (0.0%) samples, respectively, and the incidence rates of the B.1.1.7 (UK) and P.1 (Brazil/Japan) variants were calculated as 33/36 (91.7%) and 1/36 (2.8%), respectively. Using direct sequencing, del69-70, N501Y (A→T), Table 1) . The incidence rate of the UK variant was very high in the Ulsan area. Recent studies have reported that although the UK variant does not hinder vaccine-induced immunity, it may increase fatality by up to 18% compared with that due to non-UK SARS-CoV-2 variants [9, 10] . These results suggest that UK variant-infected patients need to be managed cautiously. The high incidence of the UK variant in the Ulsan area compared with other areas in Korea [11] can be attributed to the frequent entry of foreigners at the Ulsan trading port, increasing the probability of transmission of variants. Although the incidence rates of the RSA and Brazil/Japan variants were low in our study, considering some limitations, including the small sample size, single institutional nature, and use of direct sequencing rather than whole-genome sequencing for validation, a more comprehensive study is needed to confirm these preliminary results.

In conclusion, the incidence of infection due to the UK variant is very high (91.7%), whereas that due to the RSA and Brazil/ Japan variants is low in the Ulsan area of Korea. A large-scale study is required to confirm our results. Powerchek SARS-CoV-2 S-gene Mutation Detection Kit is useful for the rapid screening of SARS-CoV-2 variants.

Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea

Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19

Characteristics of SARS-CoV-2 and CO-VID-19

The variant gambit: COVID-19's next move

Structural basis for human coronavirus attachment to sialic acid receptors

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Inferring the association between the risk of COVID-19 case fatality and N501Y substitution in SARS-CoV-2

The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem

Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide

None.

None declared.